Nomura Flags 6 Indian Pharma Stocks on GLP-1 Drug Demand Surge
Nomura highlights six Indian pharma companies, including Cipla and Sun Pharma, as beneficiaries of rising global demand for GLP-1 drugs used in diabetes and obesity treatment.
Akanksha jain 
Global brokerage Nomura has identified six Indian pharmaceutical companies, including Cipla and Sun Pharma, as key beneficiaries of the rising global demand for GLP-1 drugs used in diabetes and obesity treatment, highlighting the sector’s growth potential driven by expanding therapeutic use and increasing international market demand, according to a recent market analysis.
The report underscores the growing importance of GLP-1 (glucagon-like peptide-1) receptor agonists, a class of drugs increasingly used to manage type 2 diabetes and obesity. These therapies have gained significant traction worldwide due to their dual benefits in blood sugar control and weight management, leading to a surge in demand and strong investor interest in companies positioned within this segment.
Rising Demand for GLP-1 Therapies Drives Market Interest
GLP-1 drugs have emerged as one of the fastest-growing segments in the global pharmaceutical market, driven by increasing prevalence of metabolic disorders such as diabetes and obesity. The therapies work by enhancing insulin secretion, suppressing appetite, and improving metabolic outcomes, making them highly effective for long-term disease management.
Nomura’s analysis indicates that demand for these drugs is expanding rapidly across developed and emerging markets, supported by growing awareness, improved diagnosis rates, and broader clinical adoption. The expanding use of GLP-1 therapies beyond diabetes into obesity management has further accelerated market growth.
This trend is expected to create significant opportunities for pharmaceutical companies involved in the development, manufacturing, or supply of related treatments and active pharmaceutical ingredients (APIs).
Indian Pharma Firms Positioned for Growth
The report identifies six Indian pharmaceutical companies that are well-positioned to benefit from this global demand surge, citing their capabilities in manufacturing, research, and international market presence. Among them, Cipla and Sun Pharma are highlighted due to their established footprints and potential to leverage opportunities in regulated and semi-regulated markets.
Indian pharmaceutical firms have traditionally played a strong role in the global generics market, and their cost-efficient production capabilities provide a competitive advantage in scaling up supply for high-demand drug categories such as GLP-1 therapies.
The companies are expected to benefit from increased demand for both finished formulations and key ingredients, particularly as global supply chains adjust to meet rising consumption levels.
Expanding Role in Diabetes and Obesity Care
The growing adoption of GLP-1 drugs reflects broader shifts in the management of chronic diseases, particularly diabetes and obesity, which are among the leading public health challenges globally. The increasing burden of these conditions is driving demand for effective, long-term treatment options.
Healthcare systems are placing greater emphasis on therapies that address multiple aspects of metabolic health, including weight management and cardiovascular risk reduction. GLP-1 drugs have demonstrated benefits in these areas, contributing to their rising clinical use.
Indian pharmaceutical companies are expected to play a critical role in supporting this demand by ensuring the availability of affordable treatment options, particularly in cost-sensitive markets.
Investor Sentiment and Market Dynamics
The Nomura report reflects strong investor interest in pharmaceutical companies linked to high-growth therapeutic areas. Stocks associated with GLP-1 drug production and supply chains are increasingly being viewed as attractive investment opportunities due to their potential for sustained revenue growth.
Market analysts note that companies with diversified portfolios and strong export capabilities are better positioned to capitalise on global trends. The focus on GLP-1 therapies also aligns with broader investment themes centered on chronic disease management and innovation in drug development.
At the same time, competitive pressures and regulatory requirements remain key considerations, as companies seek to maintain quality standards and secure approvals in international markets.
Industry Outlook and Strategic Positioning
The report highlights the importance of strategic positioning for pharmaceutical companies aiming to capture opportunities in the GLP-1 segment. Investments in research and development, manufacturing capacity, and regulatory compliance will be critical in sustaining growth.
As global demand continues to rise, companies are expected to expand their capabilities to meet market needs while navigating pricing dynamics and competition. The evolving landscape of diabetes and obesity treatment presents both opportunities and challenges for industry players.
Nomura’s assessment underscores the growing significance of metabolic health therapies in shaping the future of the pharmaceutical industry, with Indian companies playing an increasingly important role in global supply chains and healthcare delivery.
